familial Alzheimer's disease type 2 (FAD2), apo E4 associated

From Aaushi
Jump to navigation Jump to search

Epidemiology

  • FAD2 accounts for 50% of AD cases.[1]

Pathology

Clinical significance

More general terms

References

  1. 1.0 1.1 Lendon & Craddock, Trends in the Neurosciences 24:557, 2001
  2. 2.0 2.1 2.2 Yamaguchi et al, J. Neuropathol Exp Neurol 60:731, 2001
  3. Lauderback et al, Brain Res 924:90, 2002
  4. 4.0 4.1 Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
  5. 5.0 5.1 Lane-Donovan C, Herz J. ApoE, ApoE Receptors, and the synapse in Alzheimer's disease. Trends Endocrinol Metab. 2017;28(4):273-284 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28057414 PMCID: PMC5366078Free PMC article https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(16)30170-9
  6. 6.0 6.1 Uddin MS, Kabir MT, Al Mamun A et al. APOE and Alzheimer's disease: evidence mounts that targeting APOE4 may combat Alzheimer's pathogenesis. Mol Neurobiol. 2019;56(4):2450-2465 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30032423 https://link.springer.com/article/10.1007/s12035-018-1237-z
  7. 7.0 7.1 Zhao N, Liu CC, Qiao W, et al. Apolipoprotein E, receptors, and modulation of Alzheimer's disease. Biol Psychiatry. 2018;83(4):347-357 PMID: https://www.ncbi.nlm.nih.gov/pubmed/28434655 PMCID: PMC5599322Free PMC article https://www.biologicalpsychiatryjournal.com/article/S0006-3223(17)31358-6/fulltext

Database